A Phase 3 interventional study of Docetaxel and Leuprolide in Prostatic Neoplasms, sponsored by Sanofi. Terminated at 9 sites in 9 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-04.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies testing docetaxel in Prostatic Neoplasms — 15 open to participants now, 24 under way, 10 of them phase 3. Docetaxel · Prostatic Neoplasms.
Among the 193 studies testing docetaxel in Prostatic Neoplasms, this one is the 14th largest by enrollment of the 185 interventional ones that give a count, is one of 20 that started in 2007, is one of 30 in phase 3, and was the 94th registered.
7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →15 of the 193 studies testing docetaxel in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+ · Men only
Charles Drew University of Medicine and Science · Sites in United States
Ages 18+ · Men only
Instituto do Cancer do Estado de São Paulo · Sites in Brazil
Ages 18+ · Men only
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD · Sites in France, Germany, Italy and 2 more countries
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 131 · Phase 3 34 · Phase 4 1
First in 1998; this study’s year is marked. 20 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 413 is above the median of 60 across 5,354 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 39 across the 185 interventional studies. Of the 143 that completed or were terminated, 53 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 193 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
34 studies in Prostatic Neoplasms by Sanofi: none open now, none under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 34 studies in Prostatic Neoplasms by Sanofi, this one is the 6th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2007, is one of 10 in phase 3, and was the 13th registered.
Sanofi’s Prostatic Neoplasms studies by the year they started, since 2001.
6 of the studies testing docetaxel in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT03574571Phase 3Memorial Sloan Kettering Cancer CenterA Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer | 2027-04-01 |
| NCT06480110Rigshospitalet, DenmarkEbastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | 2026-12-01 |
| NCT04633252National Cancer Institute (NCI)A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer | 2026-12-31 |
| NCT04015622British Columbia Cancer AgencyPROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA | 2027-01-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 193 studies testing docetaxel in Prostatic Neoplasms, from their registry updates:
Among Sanofi’s 34 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective was to evaluate and compare the efficacy of androgen deprivation with or without docetaxel as determined by the median progression free survival (PFS) over the period of 18-month therapy and at least 18-month follow-up.
The secondary objectives were:
The duration of the study per participant was to be at least 36 months, of which the treatment period was 18 months for all participants, followed by at least 18 months follow-up period.
Participants received study treatment for up to 18 months from the time of study therapy initiation or less if one of the following occurred: disease progression, unacceptable toxicity, death, participant refusal or treatment delay beyond the time frame that is permitted for each treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate organ function as defined by the following laboratory criteria:
Exclusion Criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received docetaxel 75 milligram per square meter (mg/m\^2) intravenous infusion over 1 hour every 3 weeks up to 10 cycles (3 week cycle) along with leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
Drug: Docetaxel · Drug: Leuprolide · Drug: Bicalutamide
Participants received leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
Drug: Leuprolide · Drug: Bicalutamide
75 mg/m\^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.
Also known as: TAXOTERE®, XRP6976
22.5 mg injection subcutaneously every 12 weeks up to 18 months.
Also known as: Eligard®
50 mg tablet orally once daily for first 4 weeks of treatment.
Median Progression-Free Survival (PFS) in Intent-to-treat (ITT) Population
PFS was the time from randomization to the date of first documented prostate specific antigen (PSA) progression, or radiographic progression, or death due to prostate cancer in the absence of previous documentation of disease progression, whichever occurred first. PSA progression was determined as: a) During treatment period: a 50 percent (%) increase from baseline, which was confirmed by a second value; b) During follow-up: detectable PSA (defined as PSA greater than or equal to 0.05 nanogram per millimeter \[ng/mL\]), which was confirmed by consecutive observation (not less than 2 weeks apart). Median PFS was estimated using the Kaplan-Meier method.
Time frame: Randomization until PSA progression or radiographic progression or death due to prostate cancer, assessed up to Month 60
Progression-Free Survival (PFS) Rate at Month 36 in ITT Population
PFS rate at Month 36 was defined as probability of being progression-free at Month 36. PFS rate was estimated using the Kaplan-Meier method.
Time frame: Month 36
Median Progression-Free Survival (PFS) in Testosterone Specific Evaluable Population
PFS was the time from randomization to the date of first documented PSA progression, or radiographic progression, or death due to prostate cancer in the absence of previous documentation of disease progression, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
Time frame: Randomization until PSA progression or radiographic progression or death due to prostate cancer, assessed up to Month 60
Progression-Free Survival (PFS) Rate at Month 36 in Testosterone Specific Evaluable Population
PFS rate at Month 36 was defined as probability of being progression-free at Month 36. PFS rate was estimated using the Kaplan-Meier method.
Time frame: Month 36
Overall Survival (OS): Number of Participants Who Died (All Cause)
The OS was the time interval from the date of randomization to the date of death due to any cause. OS was to be analyzed using the Kaplan-Meier method. However, the analysis was not performed due to insufficient number of events. Reported is the number of participants who died from any cause.
Time frame: Randomization until death due to any cause, assessed up to Month 60
Cancer-Specific Survival: Number of Participants Who Died (Cancer-Specific)
The cancer-specific survival was the time from the date of randomization to the date of death due to prostate cancer. Cancer-specific survival was to be analyzed using the Kaplan-Meier method. However, the analysis was not performed due to insufficient number of events. Reported is the number of participants who died from prostate cancer.
Time frame: Randomization until death due to prostate cancer, assessed up to Month 60
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score at End of Treatment (EOT)
FACT-P is a 39-item participant questionnaire which assesses physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional prostate cancer specific concerns (12 items). All items are scored from 0 (not at all) to 4 (very much). The total FACT-P score ranges from 0-156, with higher scores representing a better quality of life with fewer symptoms. A score of 156 represents the best outcome.
Time frame: Baseline, EOT (up to Month 18)
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Trial Outcome Index (TOI) Score at EOT
Physical well-being, functional well-being, and prostate cancer concerns sub-scales of the FACT-P questionnaire were combined to calculate TOI. Total TOI score ranges from 0 to 104, with higher scores representing a better quality of life with fewer symptoms.
Time frame: Baseline, EOT (up to Month 18)
Change From Baseline in Multidimensional Assessment of Fatigue (MAF) Index Score at EOT
MAF scale consists of 16-items to measure 4 dimensions of fatigue during past week: severity (Item 1-2), distress (Item 3), degree of interference in activities of daily living (Item 4-14), and timing (Item 15-16). Item 1-14 are scored on a numeric rating scale from 1 to 10, where higher score indicate more severity/distress/interference. Item 15-16 had multiple choice responses (4 responses each). Scale Index was calculated using Item 1-15, in following steps: 1) Item 15 score converted to 1-10 scale by multiplying the score with 2.5; 2) Average score was calculated from Item 4-14; 3) Finally scale index was calculated by adding Items 1, 2, 3 scores with average score from step 2 and converted score of Item 15 from step 1. Total MAF scale index score ranges 1 (no fatigue) to 50 (severe fatigue).
Time frame: Baseline, EOT (up to Month 18)
Change From Baseline in Erectile Function Domain of International Index of Erectile Function (EF-IIEF) Total Score at EOT
EF-IIEF is a 6-item erectile function domain of IIEF. It consists of Question 1, 2, 3, 4, 5, and 15 of IIEF questionnaire. 5 questions are scored from 0 (no activity) to 5 (very high activity) and 1 question is scored from 1 (very low activity) to 5 (very high activity). Total EF-IIEF score ranges from 1 to 30, where higher score indicates high activity.
Time frame: Baseline, EOT (up to Month 18)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
TEAE: any adverse event (AE) that occurred or worsened during the on-treatment period, which was the period from first administration of study treatment until 30 days after last administration of study treatment. AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly, or medically important. Drug-related AEs were any untoward medical occurrences attributed to study drug in a participant who received study drug. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 Grade 3 (severe) and Grade 4 (life threatening/disabling) TEAEs were also reported.
Time frame: From first administration of study treatment until 30 days after the last administration of study treatment
Participants were enrolled from 53 sites in North America (the United States of America and Canada) and Europe. Study was terminated after all participants had completed treatment with docetaxel, but before all participants had completed 18 months follow-up. The termination was not due to any safety or efficacy concerns.
| Milestone | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide |
|---|---|---|
| Started | 207 | 206 |
| Treated | 196 | 204 |
| Completed study treatment | 170 | 182 |
| Testosterone-specific evaluable | 122 | 124 |
| Completed | 81 | 91 |
| Not completed | 126 | 115 |
| Withdrew: Death | 4 | 10 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Withdrawal by subject | 18 | 16 |
| Withdrew: Discontinued due to study closure | 88 | 81 |
| Withdrew: Undefined | 11 | 5 |
PFS was the time from randomization to the date of first documented prostate specific antigen (PSA) progression, or radiographic progression, or death due to prostate cancer in the absence of previous documentation of disease progression, whichever occurred first. PSA progression was determined as: a) During treatment period: a 50 percent (%) increase from baseline, which was confirmed by a second value; b) During follow-up: detectable PSA (defined as PSA greater than or equal to 0.05 nanogram per millimeter \[ng/mL\]), which was confirmed by consecutive observation (not less than 2 weeks apart). Median PFS was estimated using the Kaplan-Meier method.
| months | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide |
|---|---|---|
| Median Progression-Free Survival (PFS) in Intent-to-treat (ITT) Population | 25.4 (23.8 to 27.8) | 23.3 (22.6 to 25.1) |
PFS rate at Month 36 was defined as probability of being progression-free at Month 36. PFS rate was estimated using the Kaplan-Meier method.
| percent chance of being progression-free | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide |
|---|---|---|
| Progression-Free Survival (PFS) Rate at Month 36 in ITT Population | 15.5 (9.1 to 23.3) | 8.6 (3.8 to 16.0) |
The OS was the time interval from the date of randomization to the date of death due to any cause. OS was to be analyzed using the Kaplan-Meier method. However, the analysis was not performed due to insufficient number of events. Reported is the number of participants who died from any cause.
| participants | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide |
|---|---|---|
| Overall Survival (OS): Number of Participants Who Died (All Cause) | 4 | 11 |
The cancer-specific survival was the time from the date of randomization to the date of death due to prostate cancer. Cancer-specific survival was to be analyzed using the Kaplan-Meier method. However, the analysis was not performed due to insufficient number of events. Reported is the number of participants who died from prostate cancer.
| participants | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide |
|---|---|---|
| Cancer-Specific Survival: Number of Participants Who Died (Cancer-Specific) | 2 | 3 |
FACT-P is a 39-item participant questionnaire which assesses physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional prostate cancer specific concerns (12 items). All items are scored from 0 (not at all) to 4 (very much). The total FACT-P score ranges from 0-156, with higher scores representing a better quality of life with fewer symptoms. A score of 156 represents the best outcome.
| units on a scale | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide |
|---|---|---|
| Baseline (n=206, 205) | 121.4 ± 18.32 | 119.6 ± 17.95 |
| Change at EOT (n=186, 184) | -4.9 ± 13.55 | -3.4 ± 14.78 |
Physical well-being, functional well-being, and prostate cancer concerns sub-scales of the FACT-P questionnaire were combined to calculate TOI. Total TOI score ranges from 0 to 104, with higher scores representing a better quality of life with fewer symptoms.
| units on a scale | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide |
|---|---|---|
| Baseline (n=206, 206) | 82.1 ± 12.58 | 80.4 ± 12.52 |
| Change at EOT (n=187, 187) | -5.4 ± 10.19 | -3.1 ± 11.83 |
PFS was the time from randomization to the date of first documented PSA progression, or radiographic progression, or death due to prostate cancer in the absence of previous documentation of disease progression, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
| months | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide |
|---|---|---|
| Median Progression-Free Survival (PFS) in Testosterone Specific Evaluable Population | 25.7 (25.1 to 28.1) | 24.7 (22.8 to 25.3) |
MAF scale consists of 16-items to measure 4 dimensions of fatigue during past week: severity (Item 1-2), distress (Item 3), degree of interference in activities of daily living (Item 4-14), and timing (Item 15-16). Item 1-14 are scored on a numeric rating scale from 1 to 10, where higher score indicate more severity/distress/interference. Item 15-16 had multiple choice responses (4 responses each). Scale Index was calculated using Item 1-15, in following steps: 1) Item 15 score converted to 1-10 scale by multiplying the score with 2.5; 2) Average score was calculated from Item 4-14; 3) Finally scale index was calculated by adding Items 1, 2, 3 scores with average score from step 2 and converted score of Item 15 from step 1. Total MAF scale index score ranges 1 (no fatigue) to 50 (severe fatigue).
| units on a scale | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide |
|---|---|---|
| Baseline (n=168, 171) | 16.4 ± 7.33 | 16.6 ± 7.93 |
| Change at EOT (n=127, 144) | 4.0 ± 8.93 | 2.6 ± 8.60 |
PFS rate at Month 36 was defined as probability of being progression-free at Month 36. PFS rate was estimated using the Kaplan-Meier method.
| percent chance of being progression-free | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide |
|---|---|---|
| Progression-Free Survival (PFS) Rate at Month 36 in Testosterone Specific Evaluable Population | 15.8 (9.0 to 24.3) | 9.1 (4.0 to 16.7) |
EF-IIEF is a 6-item erectile function domain of IIEF. It consists of Question 1, 2, 3, 4, 5, and 15 of IIEF questionnaire. 5 questions are scored from 0 (no activity) to 5 (very high activity) and 1 question is scored from 1 (very low activity) to 5 (very high activity). Total EF-IIEF score ranges from 1 to 30, where higher score indicates high activity.
| units on a scale | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide |
|---|---|---|
| Baseline (n=201, 205) | 6.4 ± 8.30 | 6.8 ± 8.25 |
| Change at EOT (n=180, 186) | -3.1 ± 7.15 | -3.3 ± 7.11 |
TEAE: any adverse event (AE) that occurred or worsened during the on-treatment period, which was the period from first administration of study treatment until 30 days after last administration of study treatment. AE: any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly, or medically important. Drug-related AEs were any untoward medical occurrences attributed to study drug in a participant who received study drug. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 Grade 3 (severe) and Grade 4 (life threatening/disabling) TEAEs were also reported.
| participants | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide |
|---|---|---|
| Any TEAE | 188 | 163 |
| Any Serious AE | 49 | 20 |
| Any TEAE Resulting in Death | 0 | 1 |
| Any TEAE Leading to any Treatment Discontinuation | 35 | 1 |
| Any Grade 3-4 TEAE | 94 | 22 |
| Docetaxel Related TEAE | 183 | NA |
| Leuprolide Related TEAE | 109 | 136 |
| Bicalutamide Related TEAE | 52 | 74 |
| Any Treatment Related TEAE | 184 | 136 |
| Any Grade 3-4 Serious TEAE | 43 | 14 |
| Any TEAE Leading to Interruption of any Treatment | 77 | 1 |
Collected over From signature of the informed consent form up to the last visit in the study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Docetaxel+Leuprolide+Bicalutamide | — | 49/196 (25%) | 185/196 (94.4%) |
| Leuprolide+Bicalutamide | — | 20/204 (9.8%) | 139/204 (68.1%) |
| Event | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide |
|---|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 11/196 | 0/204 |
| NEUTROPENIABlood and lymphatic system disorders | 9/196 | 0/204 |
| ATRIAL FIBRILLATIONCardiac disorders | 3/196 | 1/204 |
| PNEUMONIAInfections and infestations | 3/196 | 0/204 |
| DIABETES MELLITUSMetabolism and nutrition disorders | 2/196 | 0/204 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 2/196 | 1/204 |
| ANGINA PECTORISCardiac disorders | 1/196 | 2/204 |
| COLON CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/196 | 2/204 |
| ANAEMIABlood and lymphatic system disorders | 1/196 | 0/204 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 1/196 | 0/204 |
| Event | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide |
|---|---|---|
| HOT FLUSHVascular disorders | 82/196 | 118/204 |
| ALOPECIASkin and subcutaneous tissue disorders | 110/196 | 3/204 |
| FATIGUEGeneral disorders | 104/196 | 58/204 |
| OEDEMA PERIPHERALGeneral disorders | 66/196 | 11/204 |
| DIARRHOEAGastrointestinal disorders | 64/196 | 7/204 |
| NAUSEAGastrointestinal disorders | 56/196 | 11/204 |
| DYSGEUSIANervous system disorders | 51/196 | 1/204 |
| NAIL DISORDERSkin and subcutaneous tissue disorders | 50/196 | 1/204 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 40/196 | 17/204 |
| NEUROPATHY PERIPHERALNervous system disorders | 37/196 | 3/204 |
Safety population included all randomized participants who received at least part of one dose of any of the study drugs.
| Age Continuous(years) | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide | Total |
|---|---|---|---|
| Mean | 65.2 ± 6.97 | 64.0 ± 6.97 | 64.6 ± 6.99 |
| Age, Customized(participants) | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide | Total |
|---|---|---|---|
| Less Than (<) 65 Years | 86 ± 43.9 | 104 ± 51.0 | 190 |
| Greater Than or Equal to (>=) 65 to < 75 Years | 95 ± 48.5 | 89 ± 43.6 | 184 |
| >= 75 Years | 15 ± 7.7 | 11 ± 5.4 | 26 |
| Sex: Female, Male(Participants) | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 196 | 204 | 400 |
| Race/Ethnicity, Customized(participants) | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide | Total |
|---|---|---|---|
| Caucasian/White | 175 | 184 | 359 |
| Black | 16 | 13 | 29 |
| Asian/Oriental | 1 | 0 | 1 |
| Others | 4 | 7 | 11 |
| Body Surface Area (BSA)(square meter (m^2)) | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide | Total |
|---|---|---|---|
| Mean | 2.05 ± 0.176 | 2.08 ± 0.194 | 2.06 ± 0.186 |
| Prior Radiation Therapy(participants) | Docetaxel+Leuprolide+Bicalutamide | Leuprolide+Bicalutamide | Total |
|---|---|---|---|
| Number | 63 | 75 | 138 |
The record gives a start of Jul 2007, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Docetaxel